Endocannabinoids and the Digestive Tract and Bladder in Health and Disease.

  title={Endocannabinoids and the Digestive Tract and Bladder in Health and Disease.},
  author={Angelo A. Izzo and Giulio G. Muccioli and Michael R. Ruggieri and Rudolf Schicho},
  journal={Handbook of experimental pharmacology},
Components of the so-called endocannabinoid system, i.e., cannabinoid receptors, endocannabinoids, as well as enzymes involved in endocannabinoid synthesis and degradation, have been identified both in the gastrointestinal and in the urinary tract. Evidence suggests that the endocannabinoid system is implicated in many gastrointestinal and urinary physiological and pathophysiological processes, including epithelial cell growth, inflammation, analgesia, and motor function. A pharmacological… 

The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease

It was not surprising to discover that the GI tract accommodates and expresses all the components of the ECS, a physiologic entity that controls tissue homeostasis with the help of endogenously produced CBs and their receptors.

Endocannabinoids in Bladder Sensory Mechanisms in Health and Diseases

Results suggest a high potential of cannabinoids to therapeutically ameliorate lower urinary tract symptoms in overactive bladder and painful bladder syndromes and significant potential for these novel therapeutics which are devoid of central nervous system psychotropic actions, and which may avoid many of the side effects of current treatments.

Medical Cannabis and Cannabinoids: An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon?

This review is an update on the role of cannabinoids in intestinal inflammation and carcinogenesis and a discussion on their potential therapeutic use.

Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer

The molecular changes of the endocannabinoid system in the pathologies of the large intestine, focusing on inflammation and cancer are described, to form a comprehensive understanding of cannabinoid interactions in colorectal cancer and intestinal bowel diseases.

Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation

Preclinical data support a novel strategy of combining these substances for the potential development of a treatment of inflammatory bowel disease and highlight the apparent additivity between phytocannabinoids and FO.

Cannabimimetic phytochemicals in the diet – an evolutionary link to food selection and metabolic stress adaptation?

  • J. Gertsch
  • Biology
    British journal of pharmacology
  • 2017
It is postulated that the mismatch of ancient lipid genes of hunter‐gatherers and pastoralists with the high‐carbohydrate diet introduced by agriculture could be compensated for via dietary modulation of the ECS.

An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse

CBD BDS, given after the inflammatory insult, attenuates injury and motility in intestinal models of inflammation and sustain the rationale of combining CBD with other minor Cannabis constituents and support the clinical development of CBD BDS for IBD treatment.

Potential Future Pharmacological Treatment of Bladder Dysfunction.

  • K. Andersson
  • Biology, Medicine
    Basic & clinical pharmacology & toxicology
  • 2016
Evidence suggests that components of the endocannabinoid system are involved in regulation of bladder function, but the roles of these channels for normal function and in pathological states have not been established, and so far adverse effects (hyperthermia) have hampered development of antagonists.

The Endocannabinoids-Microbiota Partnership in Gut-Brain Axis Homeostasis: Implications for Autism Spectrum Disorders

This narrative review puts together the vast ground of endocannabinoids and their partnership with gut microbiota, pursuing the hypothesis that the crosstalk between these two complex homeostatic systems may disclose new ideas and functional connections for the development of synergic treatments combining “gut-therapy,” nutritional intervention and pharmacological approaches.



Cannabinoids and the gut: new developments and emerging concepts.

Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies

An introduction into the functions of the endocannabinoid system in the GI tract is given, the role of the ECS in GI diseases is highlighted, and its potential pharmacological exploitation is addressed.

Cannabinoids and gastrointestinal motility: animal and human studies.

Modulation of the gut endogenous cannabinoid system may provide a useful therapeutic target for disorders of gastrointestinal motility.

Distribution and function of monoacylglycerol lipase in the gastrointestinal tract.

The endogenous cannabinoid system plays an important role in the regulation of gastrointestinal function in health and disease. Endocannabinoid levels are regulated by catabolic enzymes. Here, we

Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.

  • F. BorrelliA. Izzo
  • Medicine, Biology
    Best practice & research. Clinical endocrinology & metabolism
  • 2009

Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation.

Cannabinoids in intestinal inflammation and cancer.

Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis

Cannabidiol, a likely safe compound, prevents experimental colitis in mice and reduces colon injury and endocannabinoid changes associated with 2,4,6-dinitrobenzene sulfonic acid administration.

Inhibition of Monoacylglycerol Lipase Attenuates Nonsteroidal Anti-Inflammatory Drug-Induced Gastric Hemorrhages in Mice

Data indicate that increasing 2-AG protects against gastric damage induced by NSAIDs, and its primary catabolic enzyme MAGL offers a promising target for the development of analgesic therapeutics possessing gastroprotective properties.

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.